You may be right FGreen, but would you say the same is true about all the big boys in the pain market?
If I'm on the board of J&J and a competitor gets BIEL, I ask the CEO why he was asleep at the switch.....
It in inconceivable to me that Whelan has not made them all aware of exactly what BIEL is doing. I saw on the BIEL website somewhere that BIEL won some award as innovative product of the year or something. Memory is it was some association or media release? If I'm J&J, I've already sat down with Whelan.
I just found an article stating that J&J CEO Bill Weldon is retiring, with $143.5 million cookies, but is remaining as Chairman. Alex Gorsky is replacing him at CEO and guess what Mr. Gorsky has been doing for the last while at J&J. Here is an excerpt from the Bloomberg release March 14....
Johnson & Johnson (JNJ)’s departing Chief Executive Officer William C. Weldon will receive $143.5 million in retirement pay, the world’s second-biggest seller of health products said today in a regulatory filing.
Alex Gorsky is scheduled to take the helm of New Brunswick, New Jersey-based J&J on April 26, making him the ninth leader in the company’s 126-year history. Weldon, 63, who will remain chairman, amassed $95.1 million in deferred and long-term compensation during his 40 years with the company, where he started as a sales representative in 1971.
Weldon’s pension has a present value of $48.4 million, which he will receive in monthly payments after he retires, the company said in the filing with the Securities and Exchange Commission. His total compensation fell to $26.8 million in 2011 from $28.7 million a year earlier, the second consecutive annual decline, as the company struggled with recalls of artificial hip implants and over-the-counter drugs, and safety concerns involving vaginal mesh products.
Gorsky, who heads the devices and supply-chain units, beat out Sheri S. McCoy, the leader of the company’s branded-drug units, for the top spot. Gorsky was paid $6.8 million in total compensation in 2011 while McCoy received $8.7 million, according to the company’s filing. END
Huh???? Let's see - Mr. Gorsky heads up the "Devices Business Unit of J&J and beat out the gal heading up the "Branded Drug Business Unit"???
Patience friends - someone at J&J knows about BIEL, the already approved RecoveryRX and the applications in progress with the FDA. Bet on it!
AI
